NEW YORK, April 25, 2016 (GLOBE NEWSWIRE) — Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that its SL-401 Phase 2 clinical data update was selected for oral presentation on June 4, 2016 at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Details on the presentation are as follows:
|Title:||Results from Phase 2 registration trial of SL-401 in patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Lead-in completed, Expansion stage ongoing.|
|Presenter:||Naveen Pemmaraju, M.D., MD Anderson Cancer Center|
|Session:||Hematologic Malignancies- Leukemia, Myelodysplastic Syndromes, and Allotransplant|
|Date/Time:||Saturday, June 4, 2016; 5:00 – 5:12PM CT|
|Location:||Arie Crown Theater|
Ivan Bergstein, M.D., Stemline’s Chief Executive Officer, commented, “We are honored that ASCO has selected our Phase 2 data update for an oral presentation at this year’s annual meeting. We are also privileged to be working with world-class collaborators and institutions on this important trial and look forward to Dr. Pemmaraju’s presentation and data updates at the meeting.”
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is advancing three product candidates through clinical trials: SL-401, SL-701, and SL-801. A potentially pivotal Phase 2 trial with SL-401 is currently enrolling patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Data from the initial stage of this ongoing trial demonstrated high overall response rates (ORR), with multiple complete responses (CRs) and patients bridged to transplant. Patients continue to be followed for overall response, progression free survival (PFS) and overall survival (OS), and new patients continue to enroll into the study. Clinical studies with SL-401 are also enrolling patients with additional malignancies including acute myeloid leukemia (AML) in CR with minimal residual disease (MRD) and high-risk myeloproliferative neoplasms (MPN). A clinical study with SL-701, an immunotherapy designed to activate the immune system to attack tumors, is currently enrolling adult patients with second-line glioblastoma multiforme (GBM). SL-801, a novel oral small molecule reversible inhibitor of XPO1, is currently in a Phase 1 trial of patients with advanced solid cancers. For more information about Stemline Therapeutics, visit www.stemline.com.
Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially include: the success and timing of our clinical trials and preclinical studies for our product candidates, including site initiation, internal review board approval, scientific review committee approval, patient accrual, safety, tolerability and efficacy data observed, and input from regulatory authorities; our plans to develop and commercialize our product candidates; our available cash and investments; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to manufacture; the performance of third-party manufacturers, clinical research organizations, clinical trial sponsors and clinical trial investigators; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
CONTACT: Contact Investor Relations Stemline Therapeutics, Inc. 750 Lexington Avenue Eleventh Floor New York, NY 10022 Tel: 646-502-2307 Email: email@example.com